Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Mainz Biomed N.V (NASDAQ: MYNZ) closed the day trading at $4.73 down -3.27% from the previous closing price of $4.89. In other words, the price has decreased by -$3.27 from its previous closing price. On the day, 0.69 million shares were traded. MYNZ stock price reached its highest trading level at $4.98 during the session, while it also had its lowest trading level at $4.4.
Ratios:
For a better understanding of MYNZ, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.91 and its Current Ratio is at 0.97. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on February 14, 2025, initiated with a Buy rating and assigned the stock a target price of $14.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYNZ now has a Market Capitalization of 10508168 and an Enterprise Value of 10317824. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.67 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 11.249 whereas that against EBITDA is -0.478.
Stock Price History:
The Beta on a monthly basis for MYNZ is 0.31, which has changed by 3.548077 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, MYNZ has reached a high of $45.20, while it has fallen to a 52-week low of $3.65. The 50-Day Moving Average of the stock is -13.03%, while the 200-Day Moving Average is calculated to be -59.16%.
Shares Statistics:
Over the past 3-months, MYNZ traded about 213.95K shares per day on average, while over the past 10 days, MYNZ traded about 196010 shares per day. A total of 2.22M shares are outstanding, with a floating share count of 2.11M. Insiders hold about 4.98% of the company’s shares, while institutions hold 11.06% stake in the company. Shares short for MYNZ as of 1740700800 were 79743 with a Short Ratio of 0.37, compared to 1738281600 on 35008. Therefore, it implies a Short% of Shares Outstanding of 79743 and a Short% of Float of 3.74.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Mainz Biomed N.V (MYNZ) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$3.6, with high estimates of -$3.6 and low estimates of -$3.6.
Analysts are recommending an EPS of between -$23.6 and -$23.6 for the fiscal current year, implying an average EPS of -$23.6. EPS for the following year is -$9.2, with 1.0 analysts recommending between -$9.2 and -$9.2.
Revenue Estimates
1 analysts predict $250k in revenue for the current quarter. It ranges from a high estimate of $250k to a low estimate of $250k. As of the current estimate, Mainz Biomed N.V’s year-ago sales were $181.67kFor the next quarter, 1 analysts are estimating revenue of $300k. There is a high estimate of $300k for the next quarter, whereas the lowest estimate is $300k.
A total of 2 analysts have provided revenue estimates for MYNZ’s current fiscal year. The highest revenue estimate was $1.07M, while the lowest revenue estimate was $1.05M, resulting in an average revenue estimate of $1.06M. In the same quarter a year ago, actual revenue was $895.48kBased on 2 analysts’ estimates, the company’s revenue will be $1.25M in the next fiscal year. The high estimate is $1.4M and the low estimate is $1.1M.
